Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59
Linda Earnest(The University of Melbourne), Joseph Torresi(The University of Melbourne), Chee Wah Tan(Duke-NUS Medical School), Steven Rockman(CSL (United Kingdom)), Daniel Fernandez‐Ruiz(UNSW Sydney), Samantha L. Grimley(The University of Melbourne), William R. Heath(Peter Doherty Institute), Lauren E. Holz(The University of Melbourne), Melissa A. Edeling(The University of Melbourne), Elizabeth Vincan(The University of Melbourne), Marc Pellegrini(The University of Melbourne), Dale I. Godfrey(Peter Doherty Institute), Kanta Subbarao(Peter Doherty Institute), James P. Cooney(The University of Melbourne), Danielle E. Anderson(Peter Doherty Institute), Jason M. Mackenzie(Peter Doherty Institute), Dhiraj Hans(International Centre for Genetic Engineering and Biotechnology), Stéphanie Gras(La Trobe University), Ashley Huey Yiing Yap(The University of Melbourne), Kathryn C. Davidson(Australian Regenerative Medicine Institute), DF Purcell(Peter Doherty Institute), Chinn Yi Wong(The University of Melbourne), Lin-Fa Wang(National University of Singapore), Jamie Mumford(Peter Doherty Institute), Matthew Frieman(University of Maryland, Baltimore), Simon Collett(The University of Melbourne), Jason Roberts(Peter Doherty Institute), Julio Carrera Montoya(The University of Melbourne)
Cited by 3
Related Papers
Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2
|The EMBO Journal|2020|499
Identification of phenotypically and functionally heterogeneous mouse mucosal-associated invariant T cells using MR1 tetramers
|The Journal of Experimental Medicine|2015|381